Antidiabetic Activity of Bioactive Compounds in <i>Pleurotus florida</i> using Protein Receptors
Keywords:Molecular Docking, <i>Pleurotus florida</i>, Bioactive Compounds, GPCR40, PTPBI, PPAR and DPP4 Protein Receptor
Diabetes Mellitus (DM) is a chronic metabolic disorder due to the defects of insulin secretion (type 1) and increased cellular resistance to insulin (type 2). Mushrooms were found to be effective for reducing diabetic complications and for decreasing the blood glucose levels. When compared to synthetic drugs, the bioactive compounds isolated from mushrooms seem to be less toxic and free of side effects. The ethanol extracts of Pleurotus florida mushroom was used for the extraction of bioactive compounds. The compounds PFEE-1 to PFEE -14 were screened for drug likeness and molecular properties. For structural molecular biology and computer -assisted drug design, molecular docking is found to be a strong tool. It has been used in an attempt to identify and to expound the mechanism of action of the bioactive compounds in Pleurotus florida with the inhibition of GPCR40, PTPBI, PPAR and DPP4 protein receptor for controlling the blood sugar level. 14 bioactive compounds screened from Pleurotus florida mushroom ethanol extract was docked with the glide software based on the drug-likeness score. Ergosterol was found to be a potent inhibitor of DPP4, GPCR40, PPAR and PTPBI when compared to other bioactive compounds.
Harding, J.L., Pavkov, M.E., Magliano, D.J., Shaw, J.E. and Gregg, E.W. Global trends in diabetes complications: A review of current evidence. Diabetol., 2019, 62, 3-16. https://doi.org/10.1007/s00125-018-4711-2 DOI: https://doi.org/10.1007/s00125-018-4711-2
Reis F.S., Martins A., Vasconcelos M.H., Morales P. and Ferreira I.C. Functional foods based on extracts or compounds derived from Mushrooms. Trends Fd. Sci. Technol., 2017, 66, 48-62. doi: 10.1016/j.tifs.2017.05.010. DOI: https://doi.org/10.1016/j.tifs.2017.05.010
De Silva, D., Rapior, S., Hyde, K. and Bahkali, A. Medicinal mushrooms in prevention and control of diabetes mellitus. Fungal Diversity, 2012, 56, 1-29. https://doi.org/10.1007/s13225-012-0187-4 DOI: https://doi.org/10.1007/s13225-012-0187-4
Teng, B.S., Wang, C.D., Zhang, D., Wu, J.S., Pan, D., Pan, L.F., Yang, H.J. and Zhou, P. Hypoglycemic effect and mechanism of a proteoglycan from ganodermalucidum on streptozotocin-induced type 2 diabetic rats. Eur. Rev. Med. Pharmacolog. Sci., 2012, 16, 166-175.
Cui, B., Han, L., Qu, J. and Lv, Y. Hypoglycemic activity of Grifola frondosa rich in vanadium. Biolog. Trace Elem. Res., 2009, 131, 186-191. https://doi.org/10.1007/s12011-009-8355-4 DOI: https://doi.org/10.1007/s12011-009-8355-4
Konno, S., Aynehchi, S., Dolin, D., Schwartz, A., Choudhury, M. and Tazaki, H. Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal maitake mushroom [Grifola frondosa (Dicks.:Fr.) S.F. Gray]. Int. J. Med. Mushrooms, 2002, 4, 131-142. DOI: https://doi.org/10.1615/IntJMedMushr.v4.i3.10
Rahi, D. and Malik, D. Diversity of mushrooms and their metabolites of nutraceutical and therapeutic significance. J. Mycol., 2016, 2016, 1-18. https://doi.org/10.1155/2016/7654123 DOI: https://doi.org/10.1155/2016/7654123
Ho, L., Asyikeen Zulkifli, N. and Tan, T. An introduction to mushroom - edible mushroom: nutritional properties, potential nutraceutical values and Its Utilisation in Food Product Development. 2020. https://doi.org/10.5772/intechopen.91827 DOI: https://doi.org/10.5772/intechopen.91827
Khan, M. and Tania, M. Nutritional and medicinal importance of Pleurotus mushrooms: An overview. Fd. Rev. Int., 2012, 28, 313-329. https://doi.org/10.1080/87559129.2011.637267 DOI: https://doi.org/10.1080/87559129.2011.637267
McConkey, B.J., Sobolev, V. and Edelman, M. The performance of current methods in ligand-protein docking. Curr. Sci., 2002, 83, 845-856. http://www.jstor.org/stable/24107087
Demuth, H.U., McIntosh, C.H. and Pederson, R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochimica et Biophysica Acta, 2005, 1751, 33-44. https://doi.org/10.1016/j.bbapap.2005.05.010 DOI: https://doi.org/10.1016/j.bbapap.2005.05.010
Behme, M.T., Dupré, J. and McDonald, T.J. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocrine Disorders, 2003, 3, 3. https://doi.org/10.1186/1472-6823-3-3 DOI: https://doi.org/10.1186/1472-6823-3-3
Dupre, J., Behme, M.T., Hramiak, I.M., McFarlane, P., Williamson, M.P., Zabel, P. and McDonald, T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes, 1995, 44, 626-630. https://doi.org/10.2337/diab.44.6.626. DOI: https://doi.org/10.2337/diabetes.44.6.626
How to Cite
All the articles published in IJND are distributed under a creative commons license. The journal allows the author(s) to hold the copyright of their work (all usages allowed except for commercial purpose).
Please contact us at email@example.com for permissions related to commercial use of the article(s).